Hangzhou Minsheng Healthcare Co., Ltd. (SHE:301507)
11.84
+0.12 (1.02%)
At close: Sep 14, 2026
SHE:301507 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 851.55 | 778.67 | 638.76 | 580.36 | 545.65 | 487.91 |
Other Revenue | 2.96 | 2.96 | 2.49 | 1.37 | 1.47 | 1.66 |
| 854.51 | 781.63 | 641.25 | 581.73 | 547.12 | 489.58 | |
Revenue Growth | 20.98% | 21.89% | 10.23% | 6.33% | 11.75% | 11.41% |
Cost of Revenue | 413.01 | 384.1 | 288.19 | 225.42 | 219.47 | 169.18 |
Gross Profit | 441.5 | 397.53 | 353.06 | 356.32 | 327.65 | 320.4 |
Selling, General & Admin | 312.53 | 280.54 | 246.23 | 240.88 | 219.63 | 226.67 |
Research & Development | 21.95 | 26.08 | 23.98 | 29.56 | 27.17 | 24.07 |
Other Operating Expenses | 6.48 | 5.04 | 7.07 | 5.95 | 5.64 | 7.39 |
Operating Expenses | 339.69 | 310.4 | 277.96 | 277.3 | 252.25 | 258.51 |
Operating Income | 101.81 | 87.14 | 75.1 | 79.02 | 75.4 | 61.89 |
Interest Expense | -0.06 | -0.06 | -0.06 | -0.11 | -0.16 | -0.51 |
Interest & Investment Income | 18.71 | 22.1 | 29.5 | 13.98 | 8.79 | 10.48 |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0.06 | - | - | - |
Other Non Operating Income (Expenses) | -3.31 | -0.07 | -0.82 | -0.12 | -0.08 | 6.97 |
EBT Excluding Unusual Items | 117.17 | 109.12 | 103.66 | 92.77 | 83.95 | 78.84 |
Gain (Loss) on Sale of Investments | 19.28 | 23.88 | -0.5 | 1.06 | -0.46 | -2.65 |
Gain (Loss) on Sale of Assets | -0.22 | -0 | - | - | -0 | 0.18 |
Asset Writedown | 0.82 | -0.08 | -0 | - | -0.27 | -0.29 |
Other Unusual Items | 4.56 | 4.56 | 3.1 | 2.98 | 4.85 | 2.86 |
Pretax Income | 141.61 | 137.48 | 106.25 | 96.8 | 88.07 | 78.94 |
Income Tax Expense | 19.49 | 16.44 | 14.42 | 11.16 | 9.06 | 8.71 |
Earnings From Continuing Operations | 122.12 | 121.05 | 91.83 | 85.63 | 79.01 | 70.22 |
Minority Interest in Earnings | -2.34 | -2.26 | - | - | - | - |
Net Income | 119.78 | 118.79 | 91.83 | 85.63 | 79.01 | 70.22 |
Net Income to Common | 119.78 | 118.79 | 91.83 | 85.63 | 79.01 | 70.22 |
Net Income Growth | 23.52% | 29.35% | 7.24% | 8.38% | 12.51% | 38.46% |
Shares Outstanding (Basic) | 362 | 360 | 353 | 295 | 263 | 260 |
Shares Outstanding (Diluted) | 362 | 360 | 353 | 295 | 263 | 260 |
Shares Change | 1.51% | 1.92% | 19.61% | 12.12% | 1.26% | 9.28% |
EPS (Basic) | 0.33 | 0.33 | 0.26 | 0.29 | 0.30 | 0.27 |
EPS (Diluted) | 0.33 | 0.33 | 0.26 | 0.29 | 0.30 | 0.27 |
EPS Growth | 21.69% | 26.92% | -10.35% | -3.33% | 11.11% | 26.70% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -8.66 | -19.16 | 13.57 | 72.08 | 68.37 | 18.75 |
Free Cash Flow Per Share | -0.02 | -0.05 | 0.04 | 0.24 | 0.26 | 0.07 |
Dividend Per Share | 0.150 | 0.150 | 0.100 | 0.100 | - | - |
Dividend Growth | 50.00% | 50.00% | 0% | - | - | - |
Gross Margin | 51.67% | 50.86% | 55.06% | 61.25% | 59.89% | 65.44% |
Operating Margin | 11.92% | 11.15% | 11.71% | 13.58% | 13.78% | 12.64% |
Profit Margin | 14.02% | 15.20% | 14.32% | 14.72% | 14.44% | 14.34% |
Free Cash Flow Margin | -1.01% | -2.45% | 2.12% | 12.39% | 12.50% | 3.83% |
EBITDA | 129.59 | 114.11 | 97.47 | 105.66 | 106.79 | 91.42 |
EBITDA Margin | 15.17% | 14.60% | 15.20% | 18.16% | 19.52% | 18.67% |
D&A For EBITDA | 27.78 | 26.97 | 22.37 | 26.64 | 31.39 | 29.53 |
EBIT | 101.81 | 87.14 | 75.1 | 79.02 | 75.4 | 61.89 |
EBIT Margin | 11.92% | 11.15% | 11.71% | 13.58% | 13.78% | 12.64% |
Effective Tax Rate | 13.76% | 11.96% | 13.57% | 11.53% | 10.29% | 11.04% |
Revenue as Reported | 781.63 | 781.63 | 641.25 | 581.73 | 547.12 | - |
Advertising Expenses | - | 41.74 | 37.41 | 34.43 | 77.05 | 91.52 |